title: Development of novel peptide ligands modulating the enzyme activity of prostate-specific antigen.
abstract: Prostate-specific antigen (PSA) is a serine proteinase produced mainly by epithelial cells of the prostate. Measurement of PSA in serum is widely used for diagnosis and monitoring of prostate cancer. The major problem of the PSA determination in early diagnosis is the high false positive rate due to benign prostatic hyperplasia, but the clinical accuracy can be improved by determining the proportions of various molecular forms of PSA. The main biological function of PSA is liquefaction of the seminal gel formed after ejaculation, but PSA has also been suggested to regulate invasiveness and metastatic potential of prostatic tumors. Thus, agents binding to and affecting the function of PSA have the potential to be used for diagnosis and therapy of prostate cancer. We have developed peptides specific for PSA by using cyclic phage display peptide libraries. After deducing the amino acid sequence of the peptides by sequencing the relevant part of phage genome, the peptides were expressed as glutathione-S-transferase (GST) fusion proteins or produced by chemical synthesis. The peptides were shown to bind to PSA specifically as indicated by lack of binding to other related serine proteinases. The binding of the peptides with PSA was strongly inhibited by monoclonal antibodies specific for free PSA and they did not bind to PSA-inhibitor complexes indicating that they bind close to the active site of the enzyme. Most of the peptides enhanced the enzyme activity of PSA against a chromogenic substrate. The affinity of the peptides could be increased by including Zn2+ in the reaction mixture. These results show that peptides that bind to PSA and modulate its enzyme activity can be developed by phage display techniques. These peptides have the potential to be used for targeting of prostatic tumors and diagnostics of prostate cancer.
authors.affiliation: Department of Clinical Chemistry, Helsinki University Central Hospital, Helsinki, Finland. jari.leinonen@huch.fi
authors.forename: J
authors.initials: J
authors.lastname: Leinonen
authors.forename: P
authors.initials: P
authors.lastname: Wu
authors.forename: E
authors.initials: E
authors.lastname: Koivunen
authors.forename: A
authors.initials: A
authors.lastname: Närvänen
authors.forename: U H
authors.initials: UH
authors.lastname: Stenman
mesh_terms: D006801:Humans; D008024:Ligands; D008297:Male; D019151:Peptide Library; D010455:Peptides / Q000378:metabolism*; D017430:Prostate-Specific Antigen / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000201:enzymology / Q000276:immunology; D011485:Protein Binding; D011993:Recombinant Fusion Proteins / Q000378:metabolism; D015032:Zinc / Q000494:pharmacology
chemical_list: D008024:Ligands; D019151:Peptide Library; D010455:Peptides; D011993:Recombinant Fusion Proteins; D017430:Prostate-Specific Antigen; D015032:Zinc